


RESEARCH

Open Access



Nrf2 activation rescues stress-induced depression-like behaviour and inflammatory responses in male but not female rats

Ryan T. McCallum¹, Rachel-Karson Thériault¹, Joshua D. Manduca¹, Isaac S. B. Russell¹, Angel M. Culmer¹, Janan Shoja Doost¹, Tami A. Martino¹ and Melissa L. Perreault^{1*} 

Abstract

Background Major depressive disorder (MDD) is a recurring affective disorder that is two times more prevalent in females than males. Evidence supports immune system dysfunction as a major contributing factor to MDD, notably in a sexually dimorphic manner. Nuclear factor erythroid 2-related factor 2 (Nrf2), a regulator of antioxidant signalling during inflammation, is dysregulated in many chronic inflammatory disorders; however, its role in depression and the associated sex differences have yet to be explored. Here, we investigated the sex-specific antidepressant and cognitive effects of the potent Nrf2 activator dimethyl fumarate (DMF), as well as the associated gene expression profiles.

Methods Male and female rats were treated with vehicle or DMF (25 mg/kg) whilst subjected to 8 weeks of chronic unpredictable stress. The effect of DMF treatment on stress-induced depression- and anxiety-like behaviours, as well as deficits in recognition and spatial learning and memory were then assessed. Sex differences in hippocampal (HIP) gene expression responses were also evaluated.

Results DMF treatment during stress exposure had antidepressant effects in male but not female rats, with no anxiolytic effects in either sex. Recognition learning and memory and spatial learning and memory were impaired in chronically stressed males and females, respectively, and DMF treatment rescued these deficits. Further, chronic stress elicited sex-specific alterations in HIP gene expression, many of which were normalized in animals treated with DMF. Of note, most of the differentially expressed genes in males normalized by DMF were related to antioxidant, inflammatory or immune responses.

Conclusions Collectively, these findings may support a greater role of immune processes in males than females in a rodent model of depression. This suggests that pharmacotherapies that target Nrf2 have the potential to be an effective sex-specific treatment for depression.

Highlights

- Dimethyl fumarate had antidepressant effects in chronically stressed male rats only.
- Dimethyl fumarate rescued sex-specific learning and memory deficits induced by chronic stress.

*Correspondence:

Melissa L. Perreault
perreaum@uoguelph.ca

Full list of author information is available at the end of the article



© The Author(s) 2024, corrected publication 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

- Male and female rats exhibit different gene expression responses to chronic stress, with male rats exhibiting more alterations in inflammatory-associated genes than female rats.
- Dimethyl fumarate normalized the expression of several gene transcripts in stress-exposed male and female rats.

Keywords Sex differences, Major depressive disorder, Neuroinflammation, Nuclear factor erythroid 2-related factor 2, Dimethyl fumarate

Plain English Summary

Major depressive disorder is two times more prevalent in females than males. Further, immune system dysfunction has been shown to contribute to the development of depression, with previous studies consistently reporting chronic low-grade inflammation in depressed individuals. Not surprisingly, the immune system dysfunction associated with depression appears to be sex specific. As such, whilst anti-inflammatory drugs have shown antidepressant effects in preclinical studies, the sex differences in these effects are seldomly investigated. Thus, this study sought to determine the sex-specific antidepressant and cognitive effects of dimethyl fumarate (DMF) treatment. DMF is a drug that activates the protein nuclear factor erythroid 2-related factor 2 to initiate anti-inflammatory processes. Here, male and female rats were exposed to 8 weeks of chronic stress whilst receiving daily DMF treatment. Subsequently, their expression of depression- and anxiety-like behaviours, as well as learning and memory deficits were assessed. Alterations in gene expression were also evaluated. DMF treatment had antidepressant effects in male rats only but did not have anti-anxiety effects in either sex. The learning and memory deficits in both sexes were rescued with DMF treatment. Notably, DMF normalized several of the sex-specific gene alterations induced by chronic stress, with many of the male-specific genes relating to inflammatory processes. These data suggest that DMF may be an effective antidepressant treatment in males.

Background

Major Depressive Disorder (MDD) is a recurrent multidimensional affective disorder with a lifetime prevalence ranging from 2 to 21% worldwide [1, 2]. Given that chronic stress is an established risk factor for MDD development [3] and that females consistently have a greater behavioural sensitivity to chronic stress exposure [4–7], it is not surprising that the prevalence of MDD is two times greater in women than in men [8]. Based on the traditional monoamine hypothesis of depression, the majority of antidepressant pharmacotherapies center on enhancing central nervous system (CNS) monoamine neurotransmission [9]. However, this hypothesis is now largely accepted as a simplification of depression pathophysiology; a concept supported by the high rates of treatment resistance and relapse associated with traditional antidepressant pharmacotherapy use [10, 11]. Rather, recent evidence supports multi-system dysfunction in MDD that warrants a multi-target approach for novel sex-specific therapeutic interventions [12–14].

Immune system dysfunction has emerged as a major contributing factor for depression [14]. Specifically, psychological stress has been reported to initiate proinflammatory cascades [15, 16]. Thus, it follows that chronic low-grade inflammation has become a distinct feature in both clinical presentations [17–21] and preclinical models of MDD [22–26]. Clinically, increased CNS microglial

activation [20, 21] and plasma proinflammatory cell proliferation have been reported in MDD patients compared to healthy controls. Further, elevated proinflammatory cytokines are a robust phenotype of adult MDD [18, 19, 27, 28], with elevated serum levels of several cytokines correlating with depressive symptom severity and suicidality [19, 27, 29, 30]. In line with the clinical findings, increased microglial activation has been observed within the hippocampus (HIP) of mice in chronic despair [26] and chronic unpredictable stress (CUS) [25] models of depression, as well as in the prefrontal cortex (PFC) of rats exposed to chronic restraint stress [31]. In addition, levels of proinflammatory Th17 cells were increased in the mouse HIP following CUS [25] and in the whole brain of mice following chronic restraint test and learned helplessness [24]. CUS exposure has also been demonstrated to elicit increased mRNA expression of several proinflammatory cytokines in the HIP of male mice [22, 25] and rats [23]. Notably, the sex differences observed in depression appear to extend to the associated immune system dysfunction. For instance, at baseline female rats reportedly had greater microglial activation in the PFC than male rats; this effect was reversed following acute and chronic restraint stress [32]. Moreover, whilst Liu et al. [33] found increased microglial activation in the HIP of both male and female mice following CUS, the stress-induced alterations in cytokine expression were

sex-specific. As such, findings to date highlight the importance of including sex as a variable when investigating the neuro-immune axis in the context of MDD.

The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator of antioxidant signalling during inflammation [34]. Following oxidative stress, Nrf2 is stabilized and induces the expression of antioxidant and cytoprotective genes, including *heme oxygenase-1 (HO-1)*, *NAD(P)H quinone dehydrogenase 1 (NQO1)* and *glutamate cysteine ligase (GCL)* [34–36]. Thus, Nrf2 dysregulation commonly accompanies disorders associated with chronic inflammation [34], but it has yet to be explored in MDD. Preclinical investigations, however, that have used animal models to study aspects of depression have effectively demonstrated the impact of chronic stress exposure on Nrf2 expression. Male rats that exhibited CUS-induced depression-like behaviours also had decreased *Nrf2*, *HO-1* and *NQO1* mRNA and Nrf2 protein levels in the HIP [37]. Further, subsequent treatment of these rats with curcumin, an Nrf2 activator, reversed these behavioural and molecular phenotypes [37]. Similarly, in both the social defeat stress (SDS) and lipopolysaccharide (LPS) models of depression, male mice showed reduced Nrf2 protein levels in the PFC and HIP; a result that correlated with depression-like behaviours and that was reversed following Nrf2 activation with sulforaphane [38, 39]. Of note, Nrf2 knockout (KO) mice display a depressive phenotype [38, 40], increased serum cytokine levels, as well as increased microglial activity in the PFC and HIP [40].

Based on these findings, the potent Nrf2 activator DMF is currently under investigation for its potential as an antidepressant [23, 41, 42]. Previous studies have illustrated the ability of DMF treatment to mitigate CUS-induced behavioural despair and anhedonia in male mice [41, 42] and rats [23]. Moreover, in these same studies, DMF treatment improved recognition learning memory in the novel object recognition test [42], reversed stress-induced HIP microglial activation [42], reduced mRNA [23] and protein [42] levels of the proinflammatory cytokines interleukin (IL)-1 β and tumour necrosis factor (TNF)- α in the HIP, as well as decreased HIP levels of the oxidative stress marker malondialdehyde [23]. Taken together, these results support DMF as a potent anti-inflammatory with promising antidepressant effects in male subjects. However, whilst there is evidence to suggest sexually dimorphic effects of DMF treatment in rodent models of experimental autoimmune encephalomyelitis (EAE) [43] and Alzheimer's disease (AD) [44, 45], its sex-specific antidepressant effects have yet to be elucidated.

Therefore, to better understand the sex-specific antidepressant and cognitive effects of DMF, we evaluated the

effect of chronic DMF treatment on depression- and anxiety-like behaviours, learning and memory, and HIP gene expression profiles in both male and female rats exposed to CUS.

Methods

Animals

Sixty male and female young adult Wistar rats of approximately the same age were used, with females weighing on average 210 g and males weighing on average 250 g at the beginning of the study. Following arrival, rodents were housed in same sex groups of three in ventilated cages with access to water and food ad libitum. Rodents were housed in a temperature-controlled colony room (temperature 21 °C, humidity 30–45%) and maintained on a 12-h reverse light–dark cycle (08:00 lights off; 20:00 lights on) unless otherwise noted. On the first day of the CUS protocol rodents were relocated to non-ventilated, wire-roofed, opaque individual cages for the remainder of the study. No enrichment was provided, and animals were food restricted to 15–20 g of 18% rodent chow daily, representing approximately 80% of their standard daily intake. All behavioural experiments were conducted in a red light illuminated room during the dark phase of the day–night cycle when rodents were active. All experimental procedures and protocols were approved by the Animal Care Committee of the University of Guelph and carried out in accordance with the recommendations of the Canadian Council on Animal Care.

Drugs

DMF was purchased from Sigma-Aldrich (St. Louis, MO) and administered orally at a dose of 25 mg/kg [23]. Rodents were habituated to daily consumption of 1 g of peanut butter for 5 days with DMF uniformly mixed in once CUS began. Untreated peanut butter was used as the vehicle (VEH) condition. All rats consumed 100% of the peanut butter within 5–10 min. Stainless steel feeding dishes with DMF-infused and VEH peanut butter were placed into rodent cages daily at 08:00 h and removed at 08:15 h. A 15-min feeding period allowed for consumption of the full dose.

Chronic unpredictable stress

The CUS animal model of depression is the most widely used rat model system for the study of depression as it has the greatest validity and translational potential [46–48]. The CUS schedule used in this investigation was a modified version of the protocol described previously [49]. Developed to last a total of 8 weeks, the current protocol consisted of various uncontrollable, non-debilitating, and inescapable physical, psychological,

and circadian stressors [49]. Stressors varied daily and included: cage tilt (30–45°, 8 h), cold swim (10–13 °C, 5 min), cold exposure (4 °C, 1 h), damp bedding (500 mL water, 12–14 h), food and water deprivation (24 h), lights on and off intermittently (8 h), and reverse light cycle (24 h). Each stressor was only administered once in any given week, with each weekly schedule generated randomly to prevent predictability. Stressors were continued throughout the behavioural testing period to maintain the depression-like phenotype.

Experimental design

Rodents were randomly assigned to one of six experimental groups ($N=10$ subjects per group) and included: male VEH-treated non-stressed control (male VEH); male VEH-treated CUS (CUS-VEH); male DMF-treated CUS (CUS-DMF); female VEH-treated non-stressed control (female VEH); female CUS-VEH; female CUS-DMF. Rodent weights were collected twice per week to monitor rodent health and adjust DMF dosage accordingly.

Forced swim test

The forced swim test was used to evaluate behavioural despair and any antidepressant effects of DMF [49, 50]. Rodents were placed into a 50-cm-tall Plexiglas cylinder filled with 24 ± 1 °C water to the height of 35 cm on 2 consecutive days. On day 1, rodents were placed into the cylinder for 15 min for the pre-test. 24 h later, rodents were placed in the cylinder once again for 5 min. Animals were recorded and at 5-s intervals the following parameters were measured: climbing (both front paws breaking the surface of the water whilst attempting to jump out of the cylinder), swimming (movement of limbs paddling across the water surface) or immobility (passive floating with movements only necessary to keep nose above water).

Sucrose preference test

The sucrose preference test was used to investigate anhedonia and pleasure-seeking behaviour [49]. Prior to the first test, two bottles of 1% (w/v) sucrose solution were placed in each cage for 24 h for the animals to habituate to the sucrose solution. For the following 24 h, one bottle of sucrose solution was replaced with water. Once habituation was complete, animals were deprived of food and water for 24 h, after which the sucrose preference test was conducted. Animals were given two pre-weighed bottles: one containing 1% sucrose solution and one containing water. Bottles were counterbalanced between cages and switched after every measurement. The bottles were re-weighed every hour for 3 h. The percent sucrose preference (volume sucrose solution consumed/total volume consumed * 100) was calculated.

Novel object recognition

The novel object recognition test was used to measure recognition learning and memory [51, 52]. Rodents were habituated to an open field measuring 100 cm × 100 cm × 40 cm. Habituation lasted 2 consecutive days with a single 10-min exposure on day 1 and two 10-min exposures on day 2. Testing took place on the third day. Rodents were placed into the open field facing a corner. Animals were allowed to explore two identical objects in each corner of the arena over a 4-min acquisition phase followed by a 3-min test phase 2 h later. During the test phase one of the objects was switched for a novel, unfamiliar object. The novel object was counterbalanced between rat trials with both the objects and arena cleaned between animals. The time spent exploring each object was recorded. Exploration was strictly defined as sniffing, touching, and facing the object in proximity. The discrimination ratio was calculated as the time exploring the novel object - the time exploring the familiar object / total exploration time.

Object location

The object location test was used to measure spatial learning and memory [51, 52]. The OL test was comprised of an acquisition phase and test phase, both 3 min in length respectively and separated by a 5-min delay. The acquisition phase consisted of two identical objects placed in the adjacent corners of the arena and in the test phase one object was moved to the opposite corner. Objects were counterbalanced and the area cleaned between phases and each animal. The discrimination ratio was calculated as the time exploring the novel location - the time exploring the familiar location / total exploration time.

Novelty suppressed feeding task

The novelty suppressed feeding task was employed to assess anxiety-like behaviour [53, 54] and utilizes the feeding motivation of food deprived rodents to measure exploration in an illuminated novel environment. At 48 h before testing, rodents were deprived of all food pellets for 24 h. Following this, rodents were given a brief 2-h window to feed followed by further deprivation until after the testing period on the following day. On the day of behavioural testing, the centre of the open field was illuminated (250 lumens) where a glass petri dish containing a single 18% rodent chow food pellet freshly submerged in 50% sucrose water was placed. The experimental parameters analyzed included latency to feed, and latency to first center approach with an approach was described as contact with the petri dish. A time cut-off of 10 min was established before conducting this

experiment. Immediately following the task, rats were returned to their home cage, transferred to an isolated room, and provided a single food pellet weighing ~5 g. For 10 min, rodents were monitored and scored by an experimental examiner for in-cage feeding latency and in-cage total food consumption. Concluding this in-cage observation, rodents were given 10–15 g of 18% rodent chow to compensate for the food deprivation and returned to the colony cage racks.

Gene expression

Following the behavioural tests, rats underwent rapid decapitation and dorsal HIP tissue was dissected. Total RNA was isolated from HIP tissue of male and female animals using the RNeasy Mini Kit (Qiagen, Hilden, Germany) ($N=4/\text{group}$), as previously described [55]. RNA quantity and quality were assessed by NanoDrop ND-1000 ($260/280>2$; ThermoScientific) and by RNA ScreenTape (RIN ≥ 7 ; Agilent). Whole-genome microarray analyses were performed with the Affymetrix GeneChip Rat Gene 2.0 ST microarray, which interrogates $>27,000$ protein coding transcripts, with a median of 22 probes per gene, and reproducibility at a signal correlation coefficient >0.99 . All microarray data are accessible (GEO Accession #GSE248186). Bioinformatics analyses were performed on GeneSpring GX 14.9.1 (Agilent Technologies Inc). Raw CEL files were uploaded into a project file with exon analysis and Affymetrix exon expression experiment settings and a biological significance workflow analysis. The rat gene 2.0 ST annotation technology (RaGene-2_0-st-na33_2_rn4_2013-03-28) was used for all analyses. Raw fluorescence data were normalized across all chips in each study, with a lower threshold of >60 Raw Fluorescence Units (RFU) in at least 50% of conditions. Principal Components Analysis (PCA) was used for group level clustering. Gene ontology (GO) analysis for enriched genes was performed using the NIH DAVID Bioinformatics Database, Functional Annotation Tool.

Statistical analysis

Normality tests and Levene's test for equality of variance were employed for all data. Within sex treatment group differences were analyzed using a one-way analysis of variance (ANOVA) with Treatment as the between subjects' variable and Tukey or Games-Howell post-hoc tests as appropriate. All values represented are expressed as group mean \pm standard error (SEM). Statistical analysis was performed with IBM SPSS software (Version 24, Armonk, USA).

Results

The sex-specific effects of daily DMF administration on CUS-induced behaviours were evaluated with the overall experimental timeline depicted in Fig. 1A. Graphics showing the timeline of the forced swim test and sucrose preference test are depicted in Fig. 1B and C. In male rats, CUS elevated immobility time ($p=0.002$) and reduced climbing behaviour ($p=0.01$) in the forced swim test, with no effects on total time spent swimming (Figs. 1D–F). DMF treatment to CUS-exposed rats normalized immobility time but not climbing behaviour, and significantly elevated active swimming time ($p=0.02$, Fig. 1E). Sucrose preference was suppressed by CUS in the male rats ($p=0.04$, Fig. 1G), effects that were abolished by DMF treatment (forced swim test: immobility $F(2,26)=10.2$, $p<0.001$, swimming $F(2, 26)=4.5$, $p=0.02$, climbing $F(2, 26)=4.5$, $p=0.02$; sucrose preference test: $F(2, 25)=4.8$, $p=0.02$). Over the course of the study, CUS exposure resulted in lower weight gain in the male animals ($p=0.01$, Fig. 1H), an effect that showed only minor mitigation by DMF such that the mean weights of DMF-treated rats fell in between controls and the vehicle-treated CUS-exposed group, with no statistical difference from either. In female rats, CUS elevated forced swim test immobility time ($p=0.02$, Fig. 1I) with no effects on swimming or climbing (Fig. 1J, K). Unlike that observed in the males, DMF treatment did not ameliorate the effects of CUS on immobility or alter swimming or climbing behaviour in the female rats. Similarly, CUS lowered sucrose preference ($p=0.05$, Fig. 1L) with no effects of DMF treatment [forced swim test: immobility $F(2,26)=5.5$, $p=0.01$; sucrose preference test: $F(2, 26)=7.5$, $p=0.003$]. CUS did not influence weight gain in the female animals (Fig. 1M).

The ability of DMF to ameliorate CUS-induced anxiety-like behaviour was next evaluated in the novelty suppressed feeding task and in-cage feeding (Fig. 2A). In male rats, the latency to feed in the lightened open field arena did not differ between groups (Fig. 2B). However, CUS did increase the latency to approach the centre of the arena ($p=0.01$), an effect unaltered with DMF treatment [$F(2,26)=7.5$, $p=0.003$, Fig. 2C]. Following the task, male in-cage feeding latency showed no group differences (Fig. 2D), however in-cage food consumption was suppressed by CUS ($p=0.009$) with no effect of DMF ($F(2, 27)=7.1$, $p=0.002$; Fig. 2E). In female rats (Fig. 2F–I), no group differences for any of the measures were evident except for latency to approach in the novelty suppressed feeding task whereby CUS increased the centre approach time ($p=0.04$, Fig. 2G).




Fig. 1 The effect of DMF treatment on CUS-induced depression-like behaviours and weight gain. **A** The full experimental timeline is shown. **B, C** Timelines for the forced swim test and sucrose preference test. Effect of CUS alone or combined with DMF on **D–F** immobility, swimming, and climbing behaviour in male rats during the forced swim test. **G** Male rats exposed to CUS displayed anhedonia-like behaviour in the sucrose preference test that was normalized by DMF **H** group differences in weight gain in the male rats. Effect of CUS alone or combined with DMF on **I–K** immobility, swimming, and climbing behaviour in female rats during the forced swim test. **L** CUS decreased sucrose preference with no effect of DMF. **M** Group differences in weight gain in the female animals. The data are presented as mean \pm SEM of $N=9-10$ animals per group. * $p < 0.05$ and ** $p < 0.01$ compared to vehicle and # $p < 0.05$ and ## $p < 0.01$ compared to CUS+vehicle. A one-way ANOVA followed by a Tukey or Games-Howell post-hoc test was used for all analyses

To assess spatial or recognition learning and memory the object location and novel object recognition tests were used, respectively (Fig. 3A, B). CUS with or without DMF had no significant effect on spatial learning and

memory in male rats (Fig. 3C). In the novel object recognition test, CUS induced deficits in recognition learning and memory ($p=0.05$) that were normalized by DMF ($F(2,24)=4.8, p=0.02$, Fig. 3D). Conversely, in the female




Fig. 2 The effect of DMF treatment on CUS-induced anxiety-like behaviours in the novelty suppressed feeding task (NSFT). **A** Task timeline and graphics. **B** In male rats, there were no group differences in the latency to feed in the lightened open field arena in the NSFT. **C** However, the latency to first approach the centre of the arena was increased with CUS and unchanged with DMF treatment. **D** Male in-cage feeding latency showed no group differences after the NSFT, **E** but CUS reduced in-cage food consumption, an effect unaltered by DMF treatment. **F** During the NSFT, the latency to feed in the lightened open field arena showed no group differences in female rats. **G** Whilst CUS increased the latency to first approach the centre of the arena, there was no effect of DMF. After the NSFT, there was no group differences in the female **H** in-cage feeding latency or **I** in-cage food consumption. The data are presented as mean \pm SEM of N=9–10 animals per group. * $p < 0.05$ and ** $p < 0.01$ compared to vehicle. A one-way ANOVA followed by a Tukey or Games-Howell post-hoc test was used for all analyses

animals, CUS exposure resulted in object location memory deficits ($p=0.02$) that were alleviated by DMF ($F(2, 25)=6.0, p=0.007$, Fig. 3E), with no group effects in the novel object recognition test (Fig. 3F). Collectively, these behavioural results indicate that DMF could ameliorate CUS-induced depression-like behaviour in male, but not female, rats. Further, in both sexes DMF had no impact

on CUS-induced anxiety-like behaviour, whilst improvements in CUS-induced learning and memory deficits were evident.

Gene expression changes in response to CUS and the impacts of DMF were assessed in HIP tissue. There were 134 genes altered in the HIP of CUS-exposed male rats and 116 genes altered in CUS-exposed female rats with a




Fig. 3 The effect of DMF treatment on CUS-induced learning and memory deficits. **A, B** Graphics for the object location and novel object recognition tests are shown. **C** Male animals displayed no group differences in the object location test. **D** In male rats, CUS induced deficits in the novel object recognition test that were rescued by DMF treatment. **E** In female rats, deficits in the object location test were observed with CUS exposure and these were alleviated by DMF treatment. **F** Female rats displayed no group differences in the novel object recognition test. The data are presented as mean \pm SEM of $N=9-10$ animals per group. * $p < 0.05$ compared to vehicle and # $p < 0.05$ compared to CUS + vehicle. A one-way ANOVA followed by a Tukey or Games-Howell post-hoc test was used for all analyses

\log_2 fold change ≥ 0.4 or ≤ -0.4 ($p < 0.05$) (Fig. 4A). Overall, CUS induced a downregulation in male HIP and an upregulation in female HIP of the majority of gene transcripts (Fig. 4B). Of the genes altered by CUS, 52 transcripts were changed in both sexes (Fig. 4A) with the majority identified as unknown. The 6 known gene transcripts and their encoded protein function are described in Table 1. The gene *cnppd1* was upregulated in male and female HIP tissue by CUS and the genes *chchd2*, *arhgdib*, *opalin*, *cyp2j10* were downregulated in both sexes. The gene *dusp12* was regulated in a sex-dependent manner, with elevated HIP expression in males and lower expression in females.

The top 24 most differentially expressed genes following CUS for each sex are depicted in Fig. 4C. GO analysis revealed enriched biological processes implicated in CUS-induced changes in male HIP that included processes such as “long-term memory”, “corticosteroid responses”, “glial cell differentiation”, and “oligodendrocyte differentiation” (Fig. 4D). In female HIP, the enriched biological processes were distinct and included “response to metabolic processes”, “response to organic substance”, and “response to chemical stimulus”. To evaluate the

impact of DMF on CUS-mediated gene expression changes, normalization of these CUS-induced alterations was examined, with transcripts showing a minimal \log_2 fold correction of ≥ 0.3 or ≤ -0.3 shown (Fig. 4E). In male HIP, 8 gene transcripts altered by CUS were normalized by DMF with most of these transcripts, including *nnat*, *arhgdib*, *lyz2*, *gpx3*, and *s100a11*, involved in immune or inflammatory responses or in oxidative stress (Table 2).

DMF-induced normalization of CUS-mediated upregulation of *tacr3*, which encodes the tachykinin (neurokinin 3) receptor implicated in learning and memory, as well as depression and anxiety, was also evident. The genes normalized by DMF in female rat HIP were distinct from the males (Table 3) with three of these, *tpt1*, *dcn*, and *grm2* appearing to play a role in inflammatory/immune or antioxidant responses. *Grm2*, which encodes for the metabotropic glutamate receptor 2, has also been implicated in depression and anxiety. Together these findings indicate that DMF normalizes some of the gene expression changes in HIP induced by CUS, although these changes were distinct in male and female rats.




Fig. 4 Sex-specific alterations in hippocampal gene expression in response to CUS and the mitigating effects of DMF. **A** The Venn diagram depicts the number of transcripts with a \log_2 fold change ≥ 0.4 or ≤ -0.4 in males (blue) and females (red) following CUS. **B** Volcano plots represent the $-\log_{10}(p\text{-value})$ against the $\log_2(\text{fold change})$ magnitude of transcripts altered by CUS in males (top panel) and females (bottom panel). **C** The top 24 differentially expressed genes for each sex following CUS. **D** Gene Ontology analysis identified significantly enriched terms from males (top panel) and females (bottom panel) in the categories of molecular function (orange), cellular components (green), and biological processes (blue). **E** DMF normalization of CUS-induced changes in gene expression, focusing on transcripts with a minimal \log_2 fold correction of ≥ 0.3 or ≤ -0.3

Discussion

In the present study, we demonstrated that DMF treatment during CUS exposure had antidepressant effects

in male rats only with no anxiolytic effects in either sex. CUS impaired recognition and spatial learning and memory in male and female rats, respectively; deficits

that were rescued with DMF treatment. Further, sex-specific alterations in HIP gene expression following CUS exposure were identified, several of which were normalized in animals treated with DMF. Notably, the majority of the differentially expressed genes in the male rats were related to inflammatory or immune responses. Collectively, these findings suggest that the role of immune processes in depression is sexually dimorphic, with a potentially greater role in males than in females.

Evidence supports an association between immune system dysfunction and depression [14]. As such the sex-specific effects of DMF, a potent Nrf2 activator that promotes antioxidant and anti-inflammatory mechanisms, on CUS-induced behavioural responses were explored. Here, we report that male and female rats exhibited despair- and anhedonia-like behaviours following CUS, supporting findings from previous investigations of sex differences in animal models of stress and depression-like behaviours [49, 56–61]. Regarding anhedonia-like behaviour, as measured by the sucrose preference test, it should be noted that the growth of the CUS-exposed male rats was also lower and thus may relate to the total amount of sucrose consumed. However, this consideration would not apply to females given the lack of difference in body weight across treatment groups.

DMF treatment prevented the development of depression-like behaviours in male, but not female, rats. The antidepressant effects of DMF treatment in CUS-exposed male rats are in line with previous reports [23, 41, 42]; however to our knowledge, this is the first study to report a lack of antidepressant efficacy in CUS-exposed female rats. Other reports have shown limited efficacy of DMF treatment in female rodents in other models of neuroinflammation, including the EAE rat model [43] and a transgenic mouse model of AD [44].

The development of depression-like behaviours has been linked to HIP microglial activation as it results in the release of inflammatory factors that contribute to impaired neuroplasticity and cognition [62, 63]. In addition, anti-inflammatory drugs have been shown to attenuate depressive symptoms mediated by microglial activation [64, 65]. In support of the idea that stress-induced proinflammatory mechanisms play a greater role in depression-like behaviours in male rats, our gene expression analysis revealed that most CUS-altered transcripts, normalized with DMF treatment in males, were associated with inflammatory responses or in oxidative stress. One such gene transcript was *arhgdib*, which was upregulated in stressed males and was normalized by DMF treatment in males. *Arhgdib*, which encodes Rho GDP-dissociation inhibitor β (Rho-GDI2), has been associated with oxidative stress and inflammatory responses mediated by microglia in the entorhinal,

frontal, and temporal cortices of human AD patients [66]. Elevated Rho GDI2 protein expression in HIP microglia was observed in male indoleamine-pyrrole 2,3 dioxygenase (IDO1)-knockout mice, a model of inflammation-associated depression [67]. Conversely, female rats exhibited a CUS-induced downregulation in *arhgdib* gene expression, which may suggest a reduced or lack of an inflammatory state in females exhibiting a depressive phenotype. In support of this, transgenic inactivation of astrocyte nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) in an EAE mouse model resulted in a concomitant reduction in CNS inflammation and *arhgdib* gene expression [68].

In males, the *nnat* gene transcript emerged as a potential contributor to depression-like behaviours, with CUS inducing a male-specific upregulation in *nnat* expression, subsequently rescued by DMF treatment. *Nnat* encodes neuronatin, an endoplasmic reticulum (ER) membrane protein highly expressed in the brain, implicated in cell migration, neural induction of stem cells, and maintenance of synaptic plasticity [69, 70]. Human patients with MDD exhibit increased methylation of the *nnat* promoter, indicative of repressed gene transcription, with a significant association between elevated methylation and reduced self-reported depressive symptoms following electroconvulsive therapy [71]. Further, in a stressful social loss rat model of depression, socially dominant and subordinate (depressed) male animals had lower and higher levels of the *nnat* transcript, respectively, within the posterior cortex [72]. This is consistent with our findings, suggesting that upregulated *nnat* expression is associated with a pro-depressive phenotype. Given that DMF treatment normalized *nnat* transcripts and depression-like behaviours, it is likely that proinflammatory mechanisms link this gene transcript with depression. Indeed, neuronatin activates NF- κ B in endothelial cells, resulting in increased inflammatory cytokine gene expression [73] and its expression has been associated with increased inflammatory responses in adipose tissue [74]. In addition, binding sites on the *nnat* promoter have been confirmed for the transcription factors Jun and Stat3, known to promote inflammatory signalling [74]. Interestingly, within the rat HIP, *nnat* mRNA expression was restricted to the CA2 and CA3 regions [69].

In CUS-exposed male rats, DMF normalized gene transcripts such as *s100a11* and *lyz2*, which may contribute to depression-like behaviours. The *s100a11* gene encodes calgizarrin, a calcium-binding protein that involved in inflammatory responses [75]. S100a11, induced by inflammatory cytokines, modulates p38 signalling to enhance inflammatory gene expression [75]. Moreover, in glioblastoma cells, s100a11 was shown to activate NF- κ B via annexin-2, and NF- κ B in turn had a

positive feedback effect to increase s100a11 expression [76]. Although s100a11 has not been previously linked to depression, s100a11 is upregulated in neurological and inflammatory diseases, including glioblastomas [76], amyotrophic lateral sclerosis [77], rheumatoid arthritis [78], and autoimmune encephalitis [79]. In addition, its relative protein, s100a10 (p11), is widely implicated in depression-like behaviours in a region-specific manner [80, 81]. *Lyz2* encodes for Lysozyme M (LysM), an innate immune system enzyme and microglia activation marker [82]. Recently, Li et al. [83] reported that CUS-exposed male mice exhibiting depression-like behaviours had elevated *lyz2* mRNA expression in the HIP, which parallels our findings. DMF also normalized gene transcripts in CUS-exposed female rats; however, as DMF did not elicit antidepressant effects in females, these genes may not underlie depression-like behaviours in this model.

CUS induced anxiety-like behaviours in both sexes. While this finding matches several previous studies [58, 84–86], conflicting evidence of sex-specific [56, 60] and no anxiety-like behaviours [49] following stress paradigms have also been reported. Notably, anxiety-like behaviours in either sex were not rescued with DMF treatment; however, therapeutic effects on learning and memory deficits were evident. Clinical [87, 88] and preclinical [89–91] studies support that learning and memory are impaired in depression. Moreover, DMF treatment reportedly improved learning and memory deficits in other disease models, including AD [45, 92, 93], EAE [94], systemic immune challenge [95], and hypothyroidism [96]. In the present study, only male rats were found to have deficits in recognition learning and memory following CUS; deficits that were not present in DMF-treated males exposed to CUS. This finding agrees with those from de Souza et al. [42] whereby DMF reversed CUS-induced memory alterations in the novel object recognition test in male mice. Further, these sex differences in CUS-induced recognition learning and memory deficits mostly parallel previous findings in the literature [97–101], although conflicting evidence does exist [102]. With regard to spatial learning and memory, deficits were evident in CUS-exposed female rats only and these were rescued with DMF treatment. This contradicts the current understanding of stress-induced enhancement of spatial learning and memory in female rodents [99, 100, 103–105]. Notably, these previous studies used different stress-based protocols of varying amounts and durations of stress, which has been shown to differentially alter learning and memory in both sexes [103]. For example, one week, two weeks, and three weeks of restraint stress had no impact, enhanced, and impaired spatial learning and memory, respectively, in male rats [106]. Similarly, 6 h, but not 2 h, of intermittent

restraint stress impaired spatial learning and memory in male rats [105]. Further, 6 weeks of intermittent restraint stress had no impact on spatial learning and memory in either sex, whilst 3 weeks of unpredictable intermittent stressors induced spatial learning and memory deficits in male, but not female, rats [105]. Collectively, this suggests that the discrepancy in findings may be a product of the implemented stress protocol.

The observed findings regarding learning and memory may be partially explained through concurrent alterations in gene expression. In males, elevated *nnat* expression has been implicated in recognition learning and memory. Specifically, increased *nnat* mRNA expression and protein abundance in the HIP and cortex have been shown in both apolipoprotein-D KO mice [107] and a transgenic mouse model of AD [108], both exhibiting deficits in recognition learning and memory tests. In addition, knocking down the level of *nnat* in transgenic AD mice rescued recognition learning and memory deficits [108]. *Tacr3*, another gene upregulated by CUS in males and subsequently normalized with DMF, has been implicated in learning and memory. Agonism of the tachykinin/neurokinin 3 receptor (NK3R), encoded by *tacr3*, has consistently been reported to increase cholinergic neurotransmission in the HIP, frontal cortex, and amygdala [109–111], thereby ameliorating age-related [109, 110] and scopolamine-induced [112] deficits in recognition and spatial learning and memory. Of note, pharmacological NK3R agonism in aged rats reduces *tacr3* mRNA expression in the HIP [110]. Therefore, the upregulation in HIP *tacr3* gene expression may be related to the recognition learning and memory deficits observed in this study. Although current evidence supports a role for NK3R in both recognition and spatial learning and memory in male rats [109, 110, 112, 113], this mechanism has not been investigated in the context of stress and depression. Thus, it is possible that NK3R signalling mediates task-specific learning and memory in a different pathological state.

In female rats exposed to CUS, upregulation of *grm2* expression may have contributed to the observed deficits in spatial learning and memory, given the established role of the glutamatergic system in learning and memory [114]. *Grm2* encodes for the metabotropic glutamate receptor 2 (mGlu2R), a group II mGluR that negatively regulates adenylate cyclase, leading to a reduction in intracellular cyclic AMP levels [114]. Group II receptors, predominantly located on presynaptic terminals in the HIP, PFC, and amygdala [115], modulate glutamatergic neurotransmission, long-term potentiation, and memory consolidation [114–116]. In line with this, agonism of group II mGluR (mGluR2/3) impaired spatial learning and memory in mice, whilst antagonism of

Table 1 Gene transcripts altered in both male and female rats following CUS

Male	Female	Gene	Encoded protein function
↑	↑	<i>Cnppd1</i>	Cyclin Pas1/PHO80 domain containing 1; function in brain unknown; predicted to be involved in the regulation of cyclin dependent kinase activity
↑	↓	<i>Dusp12</i>	Dual specificity phosphatase 12; MAPK phosphatase; protective against endothelial cell inflammation and oxidative stress
↓	↓	<i>Chchd2</i>	Coiled-Coil-Helix-Coiled-Coil-Helix domain containing 2; mediator of oxidative phosphorylation and repressor of the mitochondrial stress response; implicated in Parkinson's disease
↑	↓	<i>Arhgdib</i>	Rho GDP dissociation inhibitor beta; involved in immune and inflammatory responses
↓	↓	<i>Opalin</i>	Oligodendrocytic myelin paranodal and inner loop protein; transmembrane sialoglycoprotein; enriched in oligodendrocytes and involved in myelin stabilization
↓	↓	<i>Cyp2J10</i>	Cytochrome p450 enzyme; implicated in antidepressant responses

Table 2 Gene transcripts normalized by DMF in CUS-exposed male rats (absolute $\Delta\text{LogFC} > 0.3$)

GENE	CUS RESPONSE	Encoded protein function
<i>Nnat</i>	↑	Neuronatin; ER membrane protein and linked to ER stress; involved in inflammation, calcium signalling, and glucose signalling
<i>Tacr3</i>	↑	Tachykinin/neurokinin 3 receptor; promotes acetylcholine release; involved in learning and memory, implicated in anxiety and depression
<i>Arhgdib</i>	↑	Rho GDP dissociation inhibitor beta; involved in immune and inflammatory responses
<i>Lyz2</i>	↑	Lysozyme 2; marker of microglial activation; linked to immune and inflammatory responses
<i>Gpx3</i>	↑	Glutathione peroxidase 3; known target gene of Nrf2; selenoprotein of the glutathione peroxidase family; antioxidant enzyme
<i>S100a11</i>	↑	Calgizarin; calcium binding protein; implicated in pro-inflammatory processes
<i>Rpl30</i>	↓	Ribosomal protein L30; component of 60S subunit
<i>Lce1d</i>	↓	Late cornified envelope 1d; known target gene of Nrf2 in keratinocytes; function in brain unknown

Table 3 Gene transcripts normalized by DMF in CUS-exposed female rats (absolute $\Delta\text{LogFC} > 0.3$)

GENE	CUS RESPONSE	Encoded protein function
<i>Tpt1</i>	↑	Translationally-controlled tumor protein 1; Diverse functions including DNA damage repair, autophagy, protein degradation; antioxidant properties and implicated in immune responses
<i>Cnppd1</i>	↑	Cyclin Pas1/PHO80 domain containing 1; function in brain unknown; predicted to be involved in the regulation of cyclin dependent kinase activity
<i>Grm2</i>	↑	Metabotropic glutamate receptor 2; activation is anti-inflammatory; implicated in depression, stress resilience and vulnerability, anxiety
<i>Zfp46</i>	↓	Zinc finger protein 46, transcription factor; biological functional pathways unknown
<i>Olr522</i>	↓	Encodes for an olfactory receptor; specific function unknown although several functions for non-chemosensory regions in brain have been characterized
<i>Dcn</i>	↓	Decorin; extracellular matrix proteoglycan; plays a key role in inflammatory and autoimmune disorders

mGluR2/3 [115, 117] and the knockout of mGluR2 [116, 118] improved and had no effect on this measure, respectively. Despite studies using drugs that affect both group II mGluR, the mGluR2 is predominantly expressed in HIP pyramidal neurons and is likely the receptor subtype mediating these effects [119]. Thus, it follows that increased *grm2* expression in the HIP of females may contribute to the spatial learning and memory deficits exhibited.

Last, it may be of note that sex hormones have been found to influence microglia morphology and function [120], and thus are an important consideration when assessing sex differences in immune responses. However, in the context of female stress responses, results from our previous work [49] showed that CUS significantly increased estrous cycle length with some rats showing a total loss of cycling, effects that began early in the CUS paradigm. Further, we showed that depression- and

anxiety-like behaviours were not significantly different across animals in the different stages of the estrous cycle. As such, it is unlikely that the female-specific results described here were impacted by estrous cycling.

Perspectives and significance

With the high rates of treatment resistance and relapse associated with current antidepressant pharmacotherapies [10, 11] and the greater prevalence of depression in woman compared to men [8], the need for novel effective sex-specific antidepressant treatments is substantial. This is the first study to investigate the sex-specific differences in the antidepressant potential of DMF using the CUS rodent model of depression. Our findings support the notion that DMF treatment has male-specific antidepressant properties and can also rescue sex-specific deficits in learning and memory. Given that DMF is a currently approved therapeutic for the treatment of relapse-remitting multiple sclerosis (RRMS) and has been associated with improvements in self-reported depression symptoms and quality of life in RRMS patients [121], it stands that DMF treatment could serve as a practical monotherapy or adjunct therapy for male patients with MDD, and as an adjunct therapy in women experiencing cognitive deficits. Furthermore, our transcriptomic results highlight the sexual dimorphisms of the neurobiological underpinnings of depression, emphasizing the ongoing necessity for studies focused on better understanding the role of sex in the pathophysiology of neuropsychiatric disorders.

Acknowledgements

We would like to acknowledge the land in Ontario, Canada on which this research was performed, the ancestral lands of the Attawandaron people and the treaty lands and territory of the Mississaugas of the Credit First Nation. We also offer our respect to the First Nations, Inuit, and Métis peoples that reside here.

Author contributions

RTM and MLP conceived and designed the study. RTM, IR, and AMC performed the behavioural and immunohistochemistry experiments. JDM, JSD, and TAM performed the gene expression analysis. RTM, JDM, and MLP performed the data analysis and prepared the figures. RKT and MLP wrote the manuscript.

Funding

This research was supported by the Canadian Institutes of Health Research (Grant number 450186 to MLP).

Availability of data and materials

The datasets used and/or analyzed during the current study are available at the OSF repository osf.io/s49fe with gene expression data also available on the Gene Expression Omnibus.

Declarations

Ethics approval and consent to participate

All experimental procedures and protocols were approved by the Animal Care Committee of the University of Guelph and carried out in accordance with the recommendations of the Canadian Council on Animal Care (AUP# 4637).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Biomedical Sciences, University of Guelph, 50 Stone Rd. E., Guelph, ON N1G 2W1, Canada.

Received: 26 November 2023 Accepted: 31 January 2024

Published: 13 February 2024

References

- Gutiérrez-Rojas L, Porras-Segovia A, Dunne H, Andrade-González N, Cervilla JA. Prevalence and correlates of major depressive disorder: a systematic review. *Brazilian Journal of Psychiatry*. 2020;42:657–72.
- Richards D. Prevalence and clinical course of depression: a review. *Clin Psychol Rev*. 2011;31:1117–25.
- LaPlant Q, Chakravarty S, Vialou V, Mukherjee S, Koo JW, Kalahasti G, et al. Role of nuclear factor κB in ovarian hormone-mediated stress hypersensitivity in female mice. *Biol Psychiatry*. 2009;65:874–80.
- Hodes GE. Sex, stress, and epigenetics: regulation of behavior in animal models of mood disorders. *Biol Sex Differ*. 2013;4:1. <https://doi.org/10.1186/2042-6410-4-1>.
- Pfau ML, Russo SJ. Peripheral and central mechanisms of stress resilience. *Neurobiol Stress*. 2015;1:66–79.
- Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. *Lancet Psychiatry*. 2017;4:73–82. [https://doi.org/10.1016/S2215-0366\(16\)30358-3](https://doi.org/10.1016/S2215-0366(16)30358-3).
- Rincón-Cortés M, Grace AA. Sex-dependent effects of stress on immobility behavior and VTA dopamine neuron activity: modulation by ketamine. *Int J Neuropsychopharmacol*. 2017;20:823–32.
- Sloan DME, Kornstein SG. Gender differences in depression and response to antidepressant treatment. *Psychiatr Clin North Am*. 2003;26:581–94.
- Penn E, Tracy DK. The drugs don't work? Antidepressants and the current and future pharmacological management of depression. *Ther Adv Psychopharmacol*. 2012;2:179–88.
- Nestler EJ, Barrot M, Dileone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. *Neuron*. 2002;34:13–25. [https://doi.org/10.1016/S0896-6273\(02\)00653-0](https://doi.org/10.1016/S0896-6273(02)00653-0).
- McLachlan G. Treatment resistant depression: what are the options? *BMJ*. 2018;363:k5354. <https://doi.org/10.1136/bmj.k5354>.
- Delgado P. Depression: the case for a monoamine deficiency. *J Clin Psychiatry*. 2000;61:7–11.
- Rodríguez-Lavado J, Alarcón-Espósito J, Mallea M, Lorente A. A new paradigm shift in antidepressant therapy: from dual-action to multitarget-directed ligands. *Curr Med Chem*. 2022;29:4896–922.
- McCallum RT, Perreault ML. Glycogen synthase kinase-3: a focal point for advancing pathogenic inflammation in depression. *Cells*. 2021;10:2270.
- Jope RS, Cheng Y, Lowell JA, Worthen RJ, Sitbon YH, Beurel E. Stressed and inflamed, can GSK3 be blamed? *Trends Biochem Sci*. 2017;42:180–92.
- Leonard BE. The concept of depression as a dysfunction of the immune system. *Curr Immunol Rev*. 2010;6:205–12.
- Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol Psychiatry*. 2009;65:732–41.
- Myint A, Leonard B, Steinbusch H, Kim Y. Th1, Th2, and Th3 cytokine alterations in major depression. *J Affect Disord*. 2005;88:167–73.
- Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression. *PLoS ONE*. 2018;13: e0197267.
- Su L, Faluyi YO, Hong YT, Fryer TD, Mak E, Gabel S, et al. Neuroinflammatory and morphological changes in late-life depression: the NIMROD study. *Br J Psychiatry*. 2016;209:525–6.

21. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miller L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiat*. 2015;72:268.
22. Shi W, Zhang S, Lu Y, Wang Y, Zhao J, Li L. T cell responses in depressed mice induced by chronic unpredictable mild stress. *J Affect Disord*. 2022;296:150–6.
23. Abd El-Fattah AA, Fahim AT, Sadik NAH, Ali BM. Resveratrol and dimethyl fumarate ameliorate depression-like behaviour in a rat model of chronic unpredictable mild stress. *Brain Res*. 2018;1701:227–36.
24. Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. *Biol Psychiatry*. 2013;73:622–30.
25. Huang C, Zhang F, Li P, Song C. Low-dose IL-2 attenuated depression-like behaviors and pathological changes through restoring the balances between IL-6 and TGF- β and between Th17 and Treg in a chronic stress-induced mouse model of depression. *Int J Mol Sci*. 2022;23:13856.
26. Hellwig S, Brioschi S, Dieni S, Frings L, Masuch A, Blank T, et al. Altered microglia morphology and higher resilience to stress-induced depression-like behavior in CX3CR1-deficient mice. *Brain Behav Immun*. 2016;55:126–37.
27. Nahar Z, Sal-Sabil N, Sohan Md, Qusar MS, Islam MDR. Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: a case-control study results. *Health Sci Rep*. 2022;6:e1005. <https://doi.org/10.1002/hsr2.1005>.
28. Davami M, Baharlou R, Ahmadi Vasmehjani A, Ghanizadeh A, Keshtkar M, Dezhkam I, et al. Elevated IL-17 and TGF- β serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. *Basic Clin Neurosci J*. 2016;7:137–42. <https://doi.org/10.15412/J.BCN.03070207>.
29. Kim Y-K, Lee S-W, Kim S-H, Shim S-H, Han S-W, Choi S-H, et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:356–61.
30. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. *Psychosom Med*. 2003;65:362–8.
31. Hinwood M, Morandini J, Day TA, Walker FR. Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. *Cereb Cortex*. 2012;22:1442–54.
32. Bollinger JL, Bergeon Burns CM, Wellman CL. Differential effects of stress on microglial cell activation in male and female medial prefrontal cortex. *Brain Behav Immun*. 2016;52:88–97.
33. Liu L-L, Li J-M, Su W-J, Wang B, Jiang C-L. Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. *Brain Behav Immun*. 2019;81:188–97.
34. Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. Nrf2, the master regulator of anti-oxidative responses. *Int J Mol Sci*. 2017;18:2772. <https://doi.org/10.1016/j.jnutbio.2011.10.012>.
35. Bellezza I, Tucci A, Galli F, Grottelli S, Mierla AL, Pilolli F, et al. Inhibition of NF- κ B nuclear translocation via HO-1 activation underlies α -tocopheryl succinate toxicity. *J Nutr Biochem*. 2012;23:1583–91.
36. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. *Free Radic Biol Med*. 2004;36:1199–207.
37. Liao D, Lv C, Cao L, Yao D, Wu Y, Long M, et al. Curcumin attenuates chronic unpredictable mild stress-induced depressive-like behaviors via restoring changes in oxidative stress and the activation of Nrf2 signaling pathway in rats. *Oxid Med Cell Longev*. 2020;2020:9268083.
38. Yao W, Zhang J, Ishima T, Dong C, Yang C, Ren Q, et al. Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice. *Sci Rep*. 2016;6:30659.
39. Yao W, Lin S, Su J, Cao Q, Chen Y, Chen J, et al. Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents. *Transl Psychiatry*. 2021;11:140.
40. Martín-de-Saavedra MD, Budni J, Cunha MP, Gómez-Rangel V, Llorio S, del Barrio L, et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. *Psychoneuroendocrinology*. 2013;38:2010–22.
41. Iniahe L, Okpakpor E, Edosuyi O, Eseka E, Nedozi O. Ameliorative effects of dimethyl fumarate in acute and chronic murine models of depression. *Acta Poloniae Pharmaceutica Drug Res*. 2018;75:1399–407.
42. de Souza AG, Lopes IS, Filho AJMC, Cavalcante TMB, Oliveira JVS, de Carvalho MAJ, et al. Neuroprotective effects of dimethyl fumarate against depression-like behaviors via astrocytes and microglia modulation in mice: possible involvement of the HCAR2/Nrf2 signaling pathway. *Naunyn Schmiedebergs Arch Pharmacol*. 2022;395:1029–45.
43. Stojić-Vukanić Z, Kotur-Stevuljević J, Nacka-Aleksić M, Kosec D, Vujnović I, Pilipović I, et al. Sex bias in pathogenesis of autoimmune neuroinflammation: relevance for dimethyl fumarate immunomodulatory/anti-oxidant action. *Mol Neurobiol*. 2018;55:3755–3774. <https://doi.org/10.1007/s12035-017-0595-2>.
44. Möhle L, Brackhan M, Bascuñana P, Pahnke J. Dimethyl fumarate does not mitigate cognitive decline and β -amyloidosis in female APPS1 mice. *Brain Res*. 2021;1768:147579.
45. Abd El-Fatah IM, Abdelrazek HMA, Ibrahim SM, Abdallah DM, El-Abhar HS. Dimethyl fumarate abridged tauo-amyloidopathy in a D-Galactose/ovariectomy-induced Alzheimer's-like disease: modulation of AMPK/SIRT-1, AKT/CREB/BDNF, AKT/GSK-3 β , adiponectin/Adipo1R, and NF- κ B/IL-1 β /ROS trajectories. *Neurochem Int*. 2021;148:105082.
46. Antoniuk S, Bijata M, Ponimaskin E, Włodarczyk J. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. *Neurosci Biobehav Rev*. 2019;99:101–16.
47. Willner P. The chronic mild stress (CMS) model of depression: History, evaluation and usage. *Neurobiol Stress*. 2017;6:78–93.
48. Czéh B, Fuchs E, Wiborg O, Simon M. Animal models of major depression and their clinical implications. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016;4:293–310.
49. Thériault R-K, Manduca JD, Perreault ML. Sex differences in innate and adaptive neural oscillatory patterns link resilience and susceptibility to chronic stress in rats. *J Psychiatry Neurosci*. 2021;46:E258-E270. <https://doi.org/10.1503/jpn.200117>.
50. Manduca JD, Thériault RK, Williams OOF, Rasmussen DJ, Perreault ML. Transient dose-dependent effects of ketamine on neural oscillatory activity in Wistar-Kyoto rats. *Neuroscience*. 2020;441:161–75.
51. Albeely AM, Nolan CJ, Rasmussen DJ, Bailey CDC, Perreault ML. Cortical dopamine D5 receptors regulate neuronal circuit oscillatory activity and memory in rats. *CNS Neurosci Ther*. 2023;29:2469–80.
52. Albeely AM, Williams OOF, Perreault ML. GSK-3 β disrupts neuronal oscillatory function to inhibit learning and memory in male rats. *Cell Mol Neurobiol*. 2022;42:1341–53.
53. Pang TY, Renoir T, Du X, Lawrence AJ, Hannan AJ. Depression-related behaviours displayed by female C57BL/6J mice during abstinence from chronic ethanol consumption are rescued by wheel-running. *Eur J Neurosci*. 2013;37:1803–10.
54. Blasco-Serra A, González-Soler EM, Cervera-Ferri A, Teruel-Martí V, Valverde-Navarro AA. A standardization of the novelty-suppressed feeding test protocol in rats. *Neurosci Lett*. 2017;658:73–8.
55. Duong ATH, Reitz CJ, Louth EL, Creighton SD, Rasouli M, Zwaiman A, et al. The clock mechanism influences neurobiology and adaptations to heart failure in clock Δ 19/ Δ 19 mice with implications for circadian medicine. *Sci Rep*. 2019;9:4994.
56. Wingo AP, Velasco ER, Florido A, Lori A, Choi DC, Jovanovic T, et al. Expression of the PPM1F gene is regulated by stress and associated with anxiety and depression. *Biol Psychiatry*. 2018;83:284–95.
57. Dunčko R, Kiss A, Škultétyová I, Rusnák M, Ježová D. Corticotropin-releasing hormone mRNA levels in response to chronic mild stress rise in male but not in female rats while tyrosine hydroxylase mRNA levels decrease in both sexes. *Psychoneuroendocrinology*. 2001;26:77–89.
58. Xia J, Wang H, Zhang C, Liu B, Li Y, Li K, et al. The comparison of sex differences in depression-like behaviors and neuroinflammatory changes in a rat model of depression induced by chronic stress. *Front Behav Neurosci*. 2023;16:1059594. <https://doi.org/10.3389/fnbeh.2022.1059594>.
59. Harden MT, Smith SE, Niehoff JA, McCurdy CR, Taylor GT. Antidepressive effects of the κ -opioid receptor agonist salvinorin A in a rat model of anhedonia. *Behav Pharmacol*. 2012;23:710–5.

60. Shepard R, Page CE, Coutellier L. Sensitivity of the prefrontal GABAergic system to chronic stress in male and female mice: Relevance for sex differences in stress-related disorders. *Neuroscience*. 2016;332:1–12.
61. Dalla C, Antoniou K, Drossopoulou G, Xagoraris M, Kokras N, Sfrikakis A, et al. Chronic mild stress impact: are females more vulnerable? *Neuroscience*. 2005;135:703–14.
62. Singhal G, Baune BT. Microglia: an interface between the loss of neuroplasticity and depression. *Front Cell Neurosci*. 2017;11:270. <https://doi.org/10.3389/fncel.2017.00270>.
63. Walker F, Nilsson M, Jones K. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. *Curr Drug Targets*. 2013;14:1262–76.
64. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. *JAMA Psychiat*. 2014;71:1381–91.
65. Burke NN, Kerr DM, Moriarty O, Finn DP, Roche M. Minocycline modulates neuropathic pain behaviour and cortical M1–M2 microglial gene expression in a rat model of depression. *Brain Behav Immun*. 2014;42:147–56.
66. Chai K, Zhang X, Chen S, Gu H, Tang H, Cao P, et al. Application of weighted co-expression network analysis and machine learning to identify the pathological mechanism of Alzheimer's disease. *Front Aging Neurosci*. 2022;14:837770. <https://doi.org/10.3389/fnagi.2022.837770>.
67. Rodriguez-Zas SL, Wu C, Southey BR, O'Connor JC, Nixon SE, Garcia R, et al. Disruption of microglia histone acetylation and protein pathways in mice exhibiting inflammation-associated depression-like symptoms. *Psychoneuroendocrinology*. 2018;97:47–58.
68. Brambilla R, Persaud T, Hu X, Karmally S, Shestopalov VI, Dvorianchikova G, et al. Transgenic inhibition of astroglial NF- κ B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. *J Immunol*. 2009;182:2628–40.
69. Oyang EL, Davidson BC, Lee W, Poon MM. Functional characterization of the dendritically localized mRNA neuronatin in hippocampal neurons. *PLoS ONE*. 2011;6: e24879.
70. Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, Mühleisen TW, et al. Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. *Transl Psychiatry*. 2015;5:e678–e678.
71. Sirignano L, Frank J, Kranaster L, Witt SH, Streit F, Zillich L, et al. Methyloome-wide change associated with response to electroconvulsive therapy in depressed patients. *Transl Psychiatry*. 2021;11:347.
72. Kroes RA, Panksepp J, Burgdorf J, Otto NJ, Moskal JR. Modeling depression: social dominance–submission gene expression patterns in rat neocortex. *Neuroscience*. 2006;137:37–49.
73. Mzhavia N, Yu S, Ikeda S, Chu TT, Goldberg I, Dansky HM. Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice. *Diabetes*. 2008;57:2774–83.
74. Li X, Thomason PA, Withers DJ, Scott J. Bio-informatics analysis of a gene co-expression module in adipose tissue containing the diet-responsive gene Nnat. *BMC Syst Biol*. 2010;4:175.
75. Zhang L, Zhu T, Miao H, Liang B. The calcium binding protein S100A11 and its roles in diseases. *Front Cell Dev Biol*. 2021;9:693262. <https://doi.org/10.3389/fcell.2021.693262>.
76. Tu Y, Xie P, Du X, Fan L, Bao Z, Sun G, et al. S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF- κ B positive feedback loop. *J Cell Mol Med*. 2019;23:6907–18.
77. Iridoy M, Zubiri I, Zelaya M, Martinez L, Ausin K, Lachen-Montes M, et al. Neuroanatomical quantitative proteomics reveals common pathogenic biological routes between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). *Int J Mol Sci*. 2018;20:4.
78. Andrés Cerezo L, Šumová B, Prajzlerová K, Veigl D, Damgaard D, Nielsen CH, et al. Calcizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. *Arthritis Res Ther*. 2017;19:79.
79. Tsai M-H, Lin C-H, Tsai K-W, Lin M-H, Ho C-J, Lu Y-T, et al. S100A6 promotes B lymphocyte penetration through the blood–brain barrier in autoimmune encephalitis. *Front Genet*. 2019;10:1188. <https://doi.org/10.3389/fgene.2019.01188>.
80. Chen MX, Oh Y-S, Kim Y. S100A10 and its binding partners in depression and antidepressant actions. *Front Mol Neurosci*. 2022;15:953066. <https://doi.org/10.3389/fnmol.2022.953066>.
81. Seo J-S, Zhong P, Liu A, Yan Z, Greengard P. Elevation of p11 in lateral habenula mediates depression-like behavior. *Mol Psychiatry*. 2018;23:1113–9.
82. Orthgiess J, Gericke M, Immig K, Schulz A, Hirrlinger J, Bechmann I, et al. Neurons exhibit Lyz2 promoter activity in vivo: Implications for using LysM-Cre mice in myeloid cell research. *Eur J Immunol*. 2016;46:1529–32.
83. Li D, Liao Q, Tao Y, Ni S, Wang C, Xu D, et al. Downregulation of CRTCl is involved in CUMS-induced depression-like behavior in the hippocampus and its RNA sequencing analysis. *Mol Neurobiol*. 2022;59:4405–18.
84. Gaspar R, Soares-Cunha C, Domingues AV, Coimbra B, Baptista F, Pinto L, et al. The duration of stress determines sex specificities in the vulnerability to depression and in the morphologic remodeling of neurons and microglia. *Front Behav Neurosci*. 2022;16:834821. <https://doi.org/10.3389/fnbeh.2022.834821>.
85. Franceschelli A, Sens J, Herchick S, Thelen C, Pitychoutis PM. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress. *Neuroscience*. 2015;290:49–60.
86. Huynh TN, Krigbaum AM, Hanna JJ, Conrad CD. Sex differences and phase of light cycle modify chronic stress effects on anxiety and depressive-like behavior. *Behav Brain Res*. 2011;222:212–22.
87. Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. *J Affect Disord*. 2012;140:113–24.
88. Pan Z, Park C, Brietzke E, Zuckerman H, Rong C, Mansur RB, et al. Cognitive impairment in major depressive disorder. *CNS Spectr*. 2019;24:22–9.
89. Rei D, Mason X, Seo J, Gräff J, Rudenko A, Wang J, et al. Basolateral amygdala bidirectionally modulates stress-induced hippocampal learning and memory deficits through a p25/Cdk5-dependent pathway. *Proc Natl Acad Sci*. 2015;112:7291–6.
90. Kim D-M, Leem Y-H. Chronic stress-induced memory deficits are reversed by regular exercise via AMPK-mediated BDNF induction. *Neuroscience*. 2016;324:271–85.
91. Bian Y, Pan Z, Hou Z, Huang C, Li W, Zhao B. Learning, memory, and glial cell changes following recovery from chronic unpredictable stress. *Brain Res Bull*. 2012;88:471–6.
92. Rojo AI, Pajares M, García-Yagüe AJ, Buendia I, Van Leuven F, Yamamoto M, et al. Deficiency in the transcription factor NRF2 worsens tauopathy parameters in a mouse model with combined tauopathy and amyloidopathy. *Redox Biol*. 2018;18:173–80.
93. Majkutewicz I, Kurowska E, Podlacha M, Myślińska D, Grembecka B, Ruciński J, et al. Age-dependent effects of dimethyl fumarate on cognitive and neuropathological features in the streptozotocin-induced rat model of Alzheimer's disease. *Brain Res*. 2018;1686:19–33.
94. das Neves SP, Santos G, Barros C, Pereira DR, Ferreira R, Mota C, et al. Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms. *J Neuroimmunol*. 2020;340:577163.
95. Paraiso HC, Kuo P-C, Curfman ET, Moon HJ, Sweazey RD, Yen J-H, et al. Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge. *J Neuroinflammation*. 2018;15:100.
96. Pan H, Wang Y, Wang X, Yan C. Dimethyl fumarate improves cognitive impairment by enhancing hippocampal brain-derived neurotrophic factor levels in hypothyroid rats. *BMC Endocr Disord*. 2022;22:188.
97. Wei J, Yuen EY, Liu W, Li X, Zhong P, Karatsoreos IN, et al. Estrogen protects against the detrimental effects of repeated stress on glutamatergic transmission and cognition. *Mol Psychiatry*. 2014;19:588–98.
98. Gomez JL, Lewis MJ, Luine VN. The interaction of chronic restraint stress and voluntary alcohol intake: effects on spatial memory in male rats. *Alcohol*. 2012;46:499–504.
99. Beck KD, Luine VN. Sex differences in behavioral and neurochemical profiles after chronic stress. *Physiol Behav*. 2002;75:661–73.

100. Bowman RE, Micik R, Gautreaux C, Fernandez L, Luine VN. Sex-dependent changes in anxiety, memory, and monoamines following one week of stress. *Physiol Behav.* 2009;97:21–9.
101. Beck KD, Luine VN. Food deprivation modulates chronic stress effects on object recognition in male rats: role of monoamines and amino acids. *Brain Res.* 1999;830:56–71.
102. Agarwal P, Palin N, Walker SL, Glasper ER. Sex-dependent effects of paternal deprivation and chronic variable stress on novel object recognition in adult California mice (*Peromyscus californicus*). *Horm Behav.* 2020;117: 104610.
103. Luine V, Gomez J, Beck K, Bowman R. Sex differences in chronic stress effects on cognition in rodents. *Pharmacol Biochem Behav.* 2017;152:13–9.
104. Bisagno V, Grillo CA, Piroli GG, Giraldo P, McEwen B, Luine VN. Chronic stress alters amphetamine effects on behavior and synaptophysin levels in female rats. *Pharmacol Biochem Behav.* 2004;78:541–50.
105. Peay DN, Saribekyan HM, Parada PA, Hanson EM, Badaruddin BS, Judd JM, et al. Chronic unpredictable intermittent restraint stress disrupts spatial memory in male, but not female rats. *Behav Brain Res.* 2020;383: 112519.
106. Luine V, Martinez C, Villegas M, María Magariños A, McEwen BS. Restraint stress reversibly enhances spatial memory performance. *Physiol Behav.* 1996;59:27–32.
107. Sanchez D, Bajo-Grañeras R, Del Caño-Espinel M, Garcia-Centeno R, Garcia-Mateo N, Pascua-Maestro R, et al. Aging without apolipoprotein D: molecular and cellular modifications in the hippocampus and cortex. *Exp Gerontol.* 2015;67:19–47.
108. Zou H-Y, Guo L, Zhang B, Chen S, Wu X-R, Liu X-D, et al. Aberrant miR-339-5p/neuronatin signaling causes prodromal neuronal calcium dyshomeostasis in mutant presenilin mice. *J Clin Investig.* 2022;132:e149160. <https://doi.org/10.1172/JCI149160>.
109. Schäble S, Topic B, Buddenberg T, Petri D, Huston JP, de Souza Silva MA. Neurokinin-3 agonism in aged rats has anxiolytic-, antidepressant-, and promnesic-like effects and stimulates ACh release in frontal cortex, amygdala and hippocampus. *Eur Neuropsychopharmacol.* 2011;21:484–94.
110. de Souza Silva MA, Lenz B, Rotter A, Biermann T, Peters O, Ramirez A, et al. Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. *Proc Natl Acad Sci.* 2013;110:15097–102.
111. Morozova E, Wu M, Dumalska I, Alreja M. Neurokinins robustly activate the majority of septohippocampal cholinergic neurons. *Eur J Neurosci.* 2008;27:114–22.
112. Schäble S, Huston JP, Barros M, Tomaz C, de Souza Silva MA. The NK3 receptor agonist senktide ameliorates scopolamine-induced deficits in memory for object, place and temporal order. *Neurobiol Learn Mem.* 2012;97:235–40.
113. Siuciak JA, McCarthy SA, Martin AN, Chapin DS, Stock J, Nadeau DM, et al. Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. *Psychopharmacology.* 2007;194:185–95.
114. Riedel G. Glutamate receptor function in learning and memory. *Behav Brain Res.* 2003;140:1–47.
115. Moridi H, Sarihi A, Habibitabar E, Shateri H, Salehi I, Komaki A, et al. Effects of post-training administration of LY341495, as an mGluR2/3 antagonist on spatial memory deficit in rats fed with high-fat diet. *IBRO Rep.* 2020;9:241–6.
116. Higgins GA, Ballard TM, Kew JNC, Grayson Richards J, Kemp JA, Adam G, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. *Neuropharmacology.* 2004;46:907–17.
117. Pitsikas N, Kaffe E, Markou A. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. *Behav Brain Res.* 2012;230:374–9.
118. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. *Science.* 1996;273:645–7.
119. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. *J Neurosci.* 2005;25:5066–78.
120. Sullivan O, Ciernia AV. Work hard, play hard: how sexually differentiated microglia work to shape social play and reproductive behavior. *Front Behav Neurosci.* 2022;16:989011. <https://doi.org/10.3389/fnbeh.2022.989011>.
121. Ozel O, Vaughn CB, Eckert SP, Jakimovski D, Lizarraga AA, Weinstock-Guttman B. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives. *Patient Relat Outcome Meas.* 2019;10:373–84.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.